拟超3570万元拿下湖南蓝怡51%股权 明德生物一个月内两度并购

Core Viewpoint - Mingde Bio has signed an acquisition agreement to acquire 51% of Hunan Lanyi Medical Equipment Co., Ltd. for 35.71 million yuan, marking its entry into chronic disease management while continuing to focus on critical care diagnostics [1][5] Group 1: Acquisition Details - The acquisition involves a cash payment of 35.71 million yuan and will be executed through capital increase and equity acquisition [2] - After the transaction, Hunan Lanyi will become a subsidiary of Mingde Bio, with its shareholding structure adjusted accordingly [2] - Hunan Lanyi specializes in IVD instruments and reagents, particularly in glycated hemoglobin testing, which is positioned as a core product for chronic disease management [2] Group 2: Financial Performance and Projections - Hunan Lanyi is currently operating at a loss, with projected net losses of 20.68 million yuan for 2024 and 23.98 million yuan for the first three quarters of 2025 [3] - The acquisition includes a phased purchase mechanism and multiple performance guarantees, with conditions for future acquisitions based on Hunan Lanyi's financial performance from 2026 to 2028 [3][4] - If Hunan Lanyi meets specific performance criteria, Mingde Bio may acquire the remaining shares at a valuation not exceeding 504 million yuan [3] Group 3: Strategic Intent - This acquisition is part of Mingde Bio's strategy to expand its business amid pressure on its core operations, aiming to create a new growth curve through external expansion [5][6] - The company aims to integrate its critical care and chronic disease management capabilities, enhancing its service offerings across the healthcare continuum [6] - The acquisition is expected to open new market opportunities and customer bases, contributing to profit growth and breaking market barriers [6] Group 4: Financial Stability - The acquisition will be funded through the company's own resources, with payments structured to minimize cash flow impact [7] - The transaction is not expected to adversely affect the company's daily operations, financial stability, or liquidity [7]